Ziopharm concludes enrollment in IL-12 & nivolumab combination trial
Category: #health  By Mateen Dalal  Date: 2019-06-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ziopharm concludes enrollment in IL-12 & nivolumab combination trial

Controlled IL-12 platform from Ziopharm is an investigational gene therapy designed to control and induce human interleukin 12 production

Ziopharm Oncology Inc, a company that focuses on developing cell therapies and immune-oncology gene, recently announced that they have completed enrolling for third cohort of Phase 1 clinical study to evaluate Controlled IL-12 combined with the PD-1 inhibitor OPDIVO (nivolumab) to treat progressive or recurrent glioblastoma multiforme (rGBM) in adult subjects.

Investigators who will conduct this multi-central trial at the University of Texas MD Anderson Cancer in Houston, Brigham and Women’s Hospital in Boston and Northwestern university in Chicago, have expressed their interest in expanding the study. Based on the final agreement done by the Data and Safety Monitoring Board, the company expects to enroll more patients for the highest dosing level.

Ziopharm’s Chief Executive, Laurence Cooper M.D., Ph.D., said that the company has completed the enrollment of the escalated dose: Ad-RTS-hIL-12+ veledimex along with nivolumab and further explored the potential for the expansion of this combination trial which can enhance their clinical experience.

There is a clear enthusiasm to combine PD-1 inhibitors with IL-12 in the ongoing study and the company is looking forward to starting a phase 2 trial that includes Ad-RTS-Hil-12 + veledimex as well as cemiplimab in the future, Cooper informed.

Citing reliable sources, the Controlled IL-12 platform of Ziopharm is reportedly an investigational gene therapy that is designed to specifically control and induce the human interleukin 12 production, the immune system’s master-regulator. Set in the rGBM, the company has reportedly leveraged anti-tumor effects as monotherapy for Controlled IL-12 with the combination of PD-1 inhibitors.

Apparently, there was a report previously that had a data of patients suffering from serial biopsies with rGBM, which showed that Controlled IL-12 results in upregulation of PD-1 expression and sustained influx of T cells, all of which provides an intriguing rationale for the combination.

Seemingly, it is anticipated that Ziopharm shall report more data from the combination trial at medical meetings this year and into the next.

 

Source Credits- https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-completes-enrollment-controlled-il-12-plus

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...